<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T19:31:48Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:2363063" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:2363063</identifier><datestamp>2009-09-10</datestamp><setSpec>brjcancer</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://dtd.nlm.nih.gov/ns/archiving/2.3/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://dtd.nlm.nih.gov/ns/archiving/2.3/ https://dtd.nlm.nih.gov/archiving/2.3/xsd/archivearticle.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id>
      <journal-title>British Journal of Cancer</journal-title>
      <issn pub-type="ppub">0007-0920</issn>
      <issn pub-type="epub">1532-1827</issn>
      <publisher>
        <publisher-name>Nature Publishing Group</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC2363063</article-id>
      <article-id pub-id-type="pmcid">PMC2363063</article-id>
      <article-id pub-id-type="pmc-uid">2363063</article-id>
      <article-id pub-id-type="pmid">10424734</article-id>
      <article-id pub-id-type="pii">6690527</article-id>
      <article-id pub-id-type="doi">10.1038/sj.bjc.6690527</article-id>
      <article-id pub-id-type="pmid">10424734</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Regular Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>MOAT-E (ARA) is a full-length MRP/cMOAT subfamily transporter expressed in kidney and liver</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Belinsky</surname>
            <given-names>M G</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kruh</surname>
            <given-names>G D</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label>Division of Medical Sciences, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA, 19111, USA</aff>
      <pub-date pub-type="ppub">
        <month>07</month>
        <year>1999</year>
      </pub-date>
      <volume>80</volume>
      <issue>9</issue>
      <fpage>1342</fpage>
      <lpage>1349</lpage>
      <history>
        <date date-type="received">
          <day>30</day>
          <month>09</month>
          <year>1998</year>
        </date>
        <date date-type="rev-recd">
          <day>15</day>
          <month>01</month>
          <year>1999</year>
        </date>
        <date date-type="accepted">
          <day>19</day>
          <month>01</month>
          <year>1999</year>
        </date>
      </history>
      <copyright-statement>Copyright 1999, Cancer Research Campaign</copyright-statement>
      <copyright-year>1999</copyright-year>
      <permissions>
        <copyright-holder>Cancer Research Campaign</copyright-holder>
      </permissions>
      <abstract>
        <p>Multidrug resistance-associated protein (MRP) and the canalicular multispecific organic anion transporter (cMOAT) are organic anion pumps that have been linked to cytotoxic drug resistance. We previously reported the isolation of three human MRP/cMOAT-related transporters, MOAT-B (MRP4), MOAT-C (MRP5) and MOAT-D (MRP3). In the present study we describe the fourth MRP/cMOAT-related transporter. We analysed ARA, a human cDNA reported to encode a 453 residue MRP-related transporter, and found that it represents a fused transcript composed of MRP sequences and partial sequences of a novel transporter. The complete coding sequence of this novel transporter, which we designated MOAT-E, was isolated. MOAT-E encodes a 1503 residue transporter that is most closely related to MRP (45%), MOAT-D (44%) and cMOAT (39%), both in terms of amino acid identity and sharing a common topology in which â¼ 17 transmembrane spanning helices are distributed within three membrane spanning domains. RNA blot analysis indicated that MOAT-E expression is restricted to kidney and liver. These observations suggest that MOAT-E may function as an organic anion transporter involved in cellular detoxification and possibly in the hepatobiliary and renal excretion of xenobiotics and/or endogenous metabolites. Isolation of MOAT-E helps to define the MRP/cMOAT subfamily of transporters. Â© 1999 Cancer Research Campaign</p>
      </abstract>
      <kwd-group>
        <kwd>MRP</kwd>
        <kwd>cMOAT</kwd>
        <kwd>ABC transporter</kwd>
        <kwd>resistance</kwd>
      </kwd-group>
    </article-meta>
  </front>
</article>

</metadata></record></GetRecord></OAI-PMH>